Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$26.24 - $39.63 $2.64 Million - $3.98 Million
-100,451 Reduced 90.59%
10,431 $410,000
Q1 2023

May 12, 2023

SELL
$18.67 - $24.56 $2.98 Million - $3.91 Million
-159,395 Reduced 58.97%
110,882 $2.7 Million
Q4 2022

Feb 08, 2023

BUY
$17.24 - $23.95 $3.22 Million - $4.48 Million
186,872 Added 224.05%
270,277 $5.79 Million
Q3 2022

Nov 10, 2022

SELL
$9.4 - $18.59 $1.1 Million - $2.18 Million
-117,189 Reduced 58.42%
83,405 $1.5 Million
Q2 2022

Aug 10, 2022

BUY
$9.12 - $18.9 $1.62 Million - $3.37 Million
178,060 Added 790.18%
200,594 $1.93 Million
Q1 2022

May 16, 2022

SELL
$12.15 - $16.83 $27,045 - $37,463
-2,226 Reduced 8.99%
22,534 $379,000
Q4 2021

Feb 14, 2022

BUY
$13.83 - $18.78 $51,074 - $69,354
3,693 Added 17.53%
24,760 $414,000
Q3 2021

Nov 15, 2021

SELL
$7.07 - $17.5 $6,009 - $14,875
-850 Reduced 3.88%
21,067 $342,000
Q2 2021

Aug 13, 2021

BUY
$5.69 - $7.17 $4,995 - $6,295
878 Added 4.17%
21,917 $138,000
Q1 2021

May 12, 2021

BUY
$5.08 - $6.89 $76,103 - $103,219
14,981 Added 247.29%
21,039 $130,000
Q4 2020

Feb 11, 2021

BUY
$5.65 - $7.66 $26,939 - $36,522
4,768 Added 369.61%
6,058 $42,000
Q3 2020

Nov 12, 2020

SELL
$4.01 - $6.29 $773 - $1,213
-193 Reduced 13.01%
1,290 $7,000
Q1 2020

May 01, 2020

BUY
$2.83 - $8.44 $2,830 - $8,440
1,000 Added 207.04%
1,483 $5,000
Q3 2019

Nov 14, 2019

SELL
$1.09 - $1.29 $218 - $258
-200 Reduced 29.28%
483 $1,000
Q2 2019

Aug 14, 2019

BUY
$1.21 - $1.48 $826 - $1,010
683 New
683 $1,000

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.